SALT LAKE CITY, Utah — August 18, 2025 — Leads & Copy — Myriad Genetics Inc. (NASDAQ: MYGN) has announced the promotion of Ben Wheeler to Chief Financial Officer, effective August 16, 2025. Wheeler, who has been with Myriad for over 13 years, previously held roles including vice president, corporate controller, and chief financial officer, operations. Scott Leffler, the former CFO, will transition to a consulting role through September 2, 2025.
Sam Raha, President and CEO of Myriad Genetics, expressed confidence in Wheeler’s ability to help execute the company’s growth strategy. Wheeler stated his excitement for the opportunity to lead the finance team.
The company is reaffirming its financial guidance for the full-year 2025, as announced during its second quarter 2025 earnings call on August 5, 2025.
Myriad Genetics is a molecular diagnostic testing and precision medicine company focused on advancing health and well-being.
Investor Contact:
Matt Scalo
(801) 584-3532
IR@myriad.com
Media Contact:
Kate Schraml
(224) 875-4493
PR@myriad.com
Source: Myriad Genetics
